Second malignancies in essential thrombocythemia (ET): a retrospective analysis of 331 patients with long-term follow-up from a single institution

References

• Barbui T, Barosi G, Grossi A, Gugliotta L, Liberato LN, Marchetti M et al. Practice guidelines for the therapy of essential thrombocythemia. A statement from the Italian Society of Hematology, the Italian Society of Experimental Hematology and the Italian Group for Bone Marrow Transplantation. Haematologica 2004; 89: 215–232.
   PubMed Web of Science ®Google Scholar
• Passamonti F, Rumi E, Pungolino E, Malabarba L, Bertazzoni P, Valentini M, Orlandi E, Arcaini L, Brusamolino E, Pascutto C, Cazzola M, Morra E, Lazzarino M. Life expectancy and prognostic factors for survival in patients with polycythemia vera and essential thrombocythemia. Am J Med 2004; 117(10): 755–761.
   PubMed Web of Science ®Google Scholar
• Tefferi A, Murphy S. Current opinion in essential thrombocythe-mia: pathogenesis, diagnosis, and management. Blood Rev 2001; 15(3): 121–131.
   PubMed Web of Science ®Google Scholar
• Harrison CN. Current trends in essential thrombocythaemia. Br JHaematol 2002; 117: 796–808.
   PubMed Web of Science ®Google Scholar
• Cervantes F, Alvarez-Larran A, Talarn C, Gomez M, MontserratE. Myelofibrosis with myeloid metaplasia following essential thrombocythaemia: actuarial probability, presenting characteris-tics and evolution in a series of 195 patients. Br J Haematol 2002; 118: 786–790.
   PubMed Web of Science ®Google Scholar
• Sterkers Y, Preudhomme C, Lai JL et al. Acute myeloid leukemiaand myelodysplastic syndromes following Essential Thrombocythemia treated with hydroxyurea: high proportion of cases with 17p deletion. Blood 1998; 91: 616–622.
   PubMed Web of Science ®Google Scholar
• Finazzi G, Ruggeri M, Rodeghiero F, Barbui T. Second malignancies in patients with Essential Thrombocythaemia treated with busulphan and hydroxyurea: long-term follow-up of a randomized clinical trial. Br J Haematol 2000; 110: 577–583.
   PubMed Web of Science ®Google Scholar
• Murphy S. Therapeutic dilemmas: balancing the risks of bleeding,thrombosis, and leukemic transformation in myeloproliferative disorders (MPD). Thromb Haemost 1997; 78(1): 622–626.
   PubMed Web of Science ®Google Scholar
• Finazzi G, Barbui T. Efficacy and safety of hydroxyurea in patientswith essential thrombocythemia. Pathol Biol ( Paris) 2001; 49(2): 167–169.
   PubMed Web of Science ®Google Scholar
• Harrison CN. Current trends in essential thrombocythaemia. Br J Haematol 2002; 117: 796–808.
   PubMed Web of Science ®Google Scholar
• Barbui T, Finazzi G. When and how to treat essential thrombo-cythemia. N Engl J Med 2005; 353(1): 85–86.
   PubMed Web of Science ®Google Scholar
• Murphy S, Iland H, Rosenthal D, Laszlo J. Essential Thrombocythemia: an interim report from the Polycythemia Vera Study Group. Semin Hematol 1986; 23: 177–82.
   PubMed Web of Science ®Google Scholar
• Imbert M, Pierre R, Thiele J, Vardiman JW, Brunning RD, Flandrin G. Essential thrombocythaemia. In: Jaffe ES, Harris NL, Stein H, Vardiman JW (eds) Pathology and genetics. Tumours of haematopoietic and lymphoid tissues. World Health Organization Classification of Tumours. Lyon: IARC, 2001.
   Google Scholar
• Fenaux P, Simon M, Caulier MT, Lai JL, Goudemand J, Bauters F. Clinical course of essential thrombocythemia in 147 cases. Cancer 1990; 66: 549–556.
   PubMed Web of Science ®Google Scholar
• Colombi M, Radaelli F, Zocchi L, Maiolo AT. Thrombotic and hemorrhagic complications in Essential Thrombocythemia. A retrospective study of 103 patients. Cancer 1991; 67: 2926–2930.
   PubMed Web of Science ®Google Scholar
• Gooley TA, Leisenring W, Crowley JA, Storer BE. Estimation of failure probabilities in the presence of competing risks: new representation of old estimators. Stat Med 1999; 18: 695–706.
   PubMed Web of Science ®Google Scholar
• Satagopan JM, Ben-Porat L, Berwick M et al. A note on competing risks in survival data analysis. Br J Cancer 2004; 91: 1229–1235.
   PubMed Web of Science ®Google Scholar
• Gray RJ. A class of K-sample tests for comparing the cumulative incidence of a competing risk. Ann Stat 1988; 6(3): 1141–1154.
   Google Scholar
• Radaelli F, Colombi M, Calori R, Zilioli VR, Bramanti S, Iurlo A, Zanella A. Analysis of risk factors predicting thrombotic and/or haemorrhagic complications in 306 patients with Essential Thrombocythemia. Hematol Oncol 2007; 25: 1–6.
   PubMed Web of Science ®Google Scholar
• Radaelli F, Mazza R, Curioni E, Ciani A, Pomati M, Maiolo A-T. Acute megakaryocytic leukaemia in essential thrombocythemia: an unusual evolution? Eur J Haematol 2002; 69: 108–111.
   PubMed Web of Science ®Google Scholar
• Murphy S, Peterson P, Iland H, Laszlo J. Experience of the Polycythemia Vera Study Group with essential thrombocythemia: a final report on diagnostic criteria, survival and leukemic transition by treatment. Semin Hematol 1997; 34: 29–39.
   PubMed Web of Science ®Google Scholar
• Schafer AT. Thrombocytosis. N Engl J Med 2004; 350(12): 1211–1219.
   PubMed Web of Science ®Google Scholar
• Barbui T. The leukemia controversy in myeloproliferative dis-orders: is it a natural progression of disease, a secondary sequela of therapy, or a combination of both? Semin Hematol 2004; 41(2 Suppl 3): 15–17.
   PubMed Web of Science ®Google Scholar
• Passamonti F, Cazzola M. Cytoreductive therapy for patients with essential thrombocythemia at high risk of thromboembolic complications. The difficult choice of the optimal drug. Haematologica 2004; 89(11): 1284–1285.
   PubMed Web of Science ®Google Scholar
• Tefferi A. Is hydroxyurea leukemogenic in essential thrombocythe-mia? Blood 1998; 92: 1459–1460.
   PubMed Web of Science ®Google Scholar
• Finazzi G, Ruggeri M, Rodeghiero F, Barbui T. Second malignancies in patients with Essential Thrombocythaemia treated with busulphan and hydroxyurea: long-term follow-up of a randomized clinical trial. Br J Haematol 2002; 116: 923–924.
   PubMed Web of Science ®Google Scholar
• Fruchtman SM, Hoffman R. Essential Thrombocythemia. In: Hoffman R, Benz EJ, Shattil Si, Furie B, Cohen Hi, Silberstein LE, McGlave P (eds) Hematology: basic principles and practice, 4th ed. Philadelphia: Churchill Livingstone, 2005; 1277-1296.
   Google Scholar
• Liozon E, Brigaudeau C, Trimoreau F, Desangles F, Ferneaux V, Praloran V, Bordessoule D. Is treatment with hydroxyurea leukemogenic in patients with essential thrombocythemia? An analyses of three new cases of leukaemic transformation and review of the literature. Hematol Cell Ther 1997; 39: 11–18.
   PubMedGoogle Scholar